Cinclus Pharma

Financial summary, October – December 2024

• Net sales amounted to TSEK 4,580 (0).
• Operating profit (EBIT) amounted to TSEK -56,889 (-39,754).
• The result for the period was TSEK -54,259 (-44,140) and earnings (loss) per share before and after dilution were SEK -1.17 (-1.68).
• Total cash flow for the period amounted to TSEK -79,197 (-63,400).
• Cash and cash equivalents at the end of the period amounted to TSEK 566,716 (87,972).

Financial summary, January – December 2024

• Net sales amounted to TSEK 4,580 (5,959).
• Operating profit (EBIT) amounted to TSEK -169,639 (-200,976).
• The result for the period was TSEK -168,031 (-215,118) and earnings (loss) per share before and after dilution were SEK -4.54 (-8.20).
• Total cash flow for the period amounted to TSEK 476,833 (-86,294).
• Cash and cash equivalents at the end of the period amounted to TSEK 566,716 (87,972).

Significant events during the period October – December 2024

• On October 12, 2024, linaprazan glurate was presented at UEG, United European Gastroenterology Week.
• On October 29, Cinclus Pharma announced that the company had reached agreement with the European Medicines Agency’s (EMA) Paediatric Committee (PDCO) on the company’s paediatric investigation plan (PIP).
• On November 22, Cinclus Pharma announced that the company had reached an agreement with the US Food and Drug Administration (FDA) regarding the company’s pediatric study plan (iPSP).
• On November 28, Cinclus Pharma announced that the company’s board of directors has decided to carry out a new share issue and immediately repurchase 854,430 C shares.
• The shares are being issued and repurchased in accordance with the long-term incentive programs, PSP 2024/2027 and ESOP 2024/2027, which were adopted by the extraordinary general meeting on June 3, 2024.
• On December 4, the company announced that its leading drug candidate, linaprazan glurate, has received its first marketing approval for the treatment of gastroesophageal reflux disease (GERD). The approval by the National Medical Products Administration (NMPA) paves the way for commercialization in China in 2025.

Significant events after the end of the period

• No significant events have occurred after the end of the period.

PRESENTATION OF THE INTERIM REPORT
A webcast will be held on February 20, 2025, at 10:00 CET via Inderes. Link to the event
https://financialhearings.com/event/51346